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ABSTRACT
In optic neuritis (ON) inflammation precedes onset of demyelination and axonal loss. The anti-
inflammatory properties of corticosteroids may be most effective in the early inflammatory phase, but
rapid patient recruitment remains a logistic challenge. The aim of the study was to review the effect of
time to initiation of treatment on visual outcome in recurrent ON.
A retrospective case note review of patients known to our centre with recurrent ON. The primary clinical
outcome was change of best corrected high contrast visual acuity (BCVA). The secondary outcome was
the change of optical coherence tomography (OCT) thickness of the peripapillary retinal nerve fibre layer
(pRNFL) and macular ganglion cell layer (mGCL) from baseline and after a minimum of 3 months
following the episode of recurrent ON.
Of 269 patients with a previous episode of ON, 54 experienced recurrent ON. In total 40 OCT
documented episodes of relapsing ON were captured in 19 patients. Treatment within < 2 days led to
better recovery of the BCVA (+ 0.02) and mGCL (-2.4 µm) if compared to delayed treatment (BCVA - 0.2,
p=0.036, mGCL -25.6 µm, p=0.019) or no corticosteroids treatment (BCVA -0.2, p=0.045, GCL -5.0 µm,
p=0.836).
These data suggest a beneficial effect of hyperacute corticosteroid treatment. A pragmatic approach for
a prospective treatment trial should consider patients with recurrent ON for logistic reasons.
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Introduction
The North American optic neuritis treatment trial (ONTT) has influenced the medical
management of optic neuritis (ON) [Group & others 1991; Beck et al. 1992a] . Over the past 25
years new developments have changed the clinical spectrum and diagnostic work up. Whilst
testing for syphilis was mandatory in 1992 [Beck et al. 1992b] , contemporary diagnostic work
up includes testing for autoantibodies such to aquaporin 4 (AQP4) and myelin glycoprotein
(MOG) [Asgari,Owens,Frøkiaer,Stenager,Lillevang & Kyvik 2011; Petzold et al. 2014] . In addition,
retinal axonal degeneration has been established as a key pathological feature quantifiable by
retinal optical coherence tomography (OCT), a technique not included to the ONTT [Petzold et
al. 2010] . One conclusion of the ONTT, superiority of intravenous compared to oral
corticosteroid treatment, has been refuted by a recent non-inferiority trial [Le Page et al. 2015] .
In view of these new developments it is worthwhile to remember that the failure of the ONTT to
include any pharmacokinetic data and the lack of a biological plausible explanation to why oral
corticosteroids should be harmful compared to intravenous corticosteroids had already been
debated in 1992 [Achiron,Djaldetti & Ziv 1992; Moskopp 1992] .
Experimentally, inflammation of the optic nerve precedes demyelination and axonal
degeneration by two days [Shindler,Ventura,Dutt & Rostami 2008]. Irreversible damage to the
axonal cytoskeleton will occur within 5-7 days [Zhu et al. 1999] . Therefore the time window
for successful treatment initiation is narrow. Corticosteroids have anti-inflammatory and
neuroprotective properties [Rosenberg-Schaffer & Lucas 1993; Banik,Matzelle,Terry & Hogan
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1997; Sapolsky,Romero & Munck 2000] . Targeting the inflammatory phase of optic neuritis
requires rapid patient recruitment, a logistic challenge for the ONTT and all subsequent ON
trials [Petzold 2017] .Recurrent episodes of ON occur frequently in NMO and CRION, but also
affect about 5.5% of patients with multiple sclerosis (MS) [Nikoskelainen 1975;
Burman,Raininko & Fagius 2011; Petzold et al. 2014] .
Therefore is interesting to note that two studies demonstrated hyperacute corticosteroid
treatment to improve outcome in patients with Chronic Relapsing Inflammatory Optic
Neuropathy (CRION) and neuromyelitis optica (NMO) [Nakamura et al. 2010; Plant,Sibtain &
Thomas 2011] . Here we review the outcome of this practise in patients with recurrent ON for
(1) speed of treatment initiation, (2) outcome of visual acuity and (3) outcome of retinal layer
atrophy.
Results
The inclusion and exclusion of patients from the hospital database to our study is summarised as
a flow-chart (Figure 1).
The hospital database had 269 patients registered with ON. Of these OCT scans were recorded in
101. Revision of these 101 patients revealed that 47 did not have a diagnosis of optic neuritis
according to diagnostic criteria [Petzold et al. 2014] . Of the remaining 54 patients ON was
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monophasic in 35. Taken together 19 patients experienced recurrent episodes of ON whilst under
our care. These 19 patients had a total of 40 episodes of OCT documented recurrent episodes of
ON.
The median age of these 19 patients was 31 years (IQR 26-44). The baseline characteristics are
presented in Table 1. A majority of these patients suffered from RION (n=9), followed by
MSON (n=4), CRION (n=4) and NMO-ON (n=2).
The clinical subgroups were comparable for age and gender. As expected, patients with RION,
CRION and NMO-ON had more recurrent episodes of ON compared to MSON (Table 2).
The median interval of onset of symptoms and administration of corticosteroids was one day
(IQR 1-5 days). Figure 2 summarises the timing of episodes and treatment initiation per patient.
In total, 14 episodes were treated within two days, 15 episodes received delayed treatment and 11
episodes were not treated with corticosteroids. The proportional breakdown of treatment
episodes per clinical group was summarised in table 3. Most of the patients with MSON did not
received corticosteroids. In contrast all of the patients with CRION did.
Primary outcome measure: BCVA
Hyperacute corticosteroid treatment compared to no treatment
Hyperacute corticosteroid treatment initiated within two days was related with a significant
better visual outcome (BCVA +0.02) in eyes with recurrent ON (n=36) compared to eyes with
recurrent ON which were not treated (BCVA -0.2, p=0.045, Figure 3).
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Hyperacute compared to delayed corticosteroid treatment
Hyperacute treatment started within two days after symptom onset leads to a significant better
BCVA compared to delayed treatment initiation (p=0.036 , Figure 3). The subgroup analyses
showed also that the primary outcome remained significantly better comparing treatment
initiation within three days, four days, five days or six days compared to delayed initiation
(Supplementary Figure A-D, p<0.05 for all comparisons). Significance was lost after further
delay (six days, Supplementary Figure D). Likewise a treatment delay of up 14 days, as
permitted in the ONTT, did not improve on final BCVA (Supplementary Figure E).
Secondary outcome measure: OCT
In total, 70 OCT scans were analysed. Automated layer segmentation was successful in all B-
scans and none required manual correction. Because of recurrent episodes affecting either eye
only 21 episodes had appropriately timed OCT scans eligible for analyses. The change of
thickness of the pRNFL and mGCL before and after recurrent episodes ON are shown in Figure
4.
Microcystic Macular Oedema (MMO) was not noted in the OCT scans reviewed. There was
significant preservation of the mGCL for episodes treated hyperacutely with corticosteroids (2.4
µm atrophy, n=12) if compared to patients receiving delayed treatment (25.6 µm atrophy,
p=0.019, n=7, Figure 4). Consistent with the mGCL findings a larger degree of pRNFL atrophy
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was also seen with delayed treatment initiation if compared to hyperacute treatment initiation,
but this just failed to reach statistical significance (p=-0.08, Figure 4). OCT data were only
available from 3 episodes of relapsing ON from patients who did not receive any treatment
which failed to reach a statistical significance for comparisons of the pRNFL and mGCL with
either treatment group.
Subgroup analyses
In addition to the pooled data analysis subgroups were investigated by pathology in descending
group size (1) RION (n=9), MSON (n=4), CRION (n=4), NMO-ON (n=2) for treatment
initiation within two days, delayed or no treatment.
RION
The subgroup analysis of patients with RION demonstrated a significant better primary outcome
for hyperacute corticosteroid treatment in the affected eyes (∆BCVA +0.1) if compared to the 
untreated group (∆BCVA -0.2, p=0.013).  Statistical significance was not reached for the 
secondary outcome measure.
MSON
In the subgroup analysis for patients with MSON there was no statistical significant differences
between patients with hyperacute corticosteroid treatment (∆BCVA +0.2) compared to the 
untreated group (∆BCVA -0.2, p=0.15). Likewise statistical significance was missed for the 
secondary outcome measure. None of the MSON patient received delayed treatment.
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CRION
There was no statistical significant difference regarding recovery of VA in patients with CRION
receiving hyperacute treatment (∆BCVA -0.1) compared to the untreated group (∆BCVA -0.2, 
p=0.43). There was however significantly less pRNFL loss in patients with CRION who received
hyperacute treatment (1.5 µm atrophy) if compared to those with delayed treatment (8 µm
atrophy, p=0.0008). Changes for the mGCL pointed to the same direction but failed statistical
significance (p=0.12) for comparison of the hyperacute treatment group (7.8 µm atrophy) if
compared to those with delayed treatment (28 µm atrophy).
NMO-ON
There were only two patients with NMO-ON and no significant differences were observed
between these two patients for either the primary or secondary outcome measure. What was
however remarkable in this group is that one of the NMO-ON patients (#10 in Figure 2) who
experience a relapse whilst under our care, recovered a BCVA in the affected eye to 1.2 with
hyperacute corticosteroid treatment.
Discussion
This retrospective study suggests that patients with recurrent episodes of optic neuritis have a
better visual outcome if corticosteroid treatment is initiated hyperacutely. The outcome was
significantly better for both the primary and secondary outcome measures. If corticosteroid
treatment was initiated within two days of symptom onset the outcome BCVA was significantly
better compared to delayed treatment or no treatment at all. Likewise, hyperacute corticosteroid
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treatment was neuroprotective with better preservation of the mGCL, with atrophy about 12-
times more severe with delayed treatment initiation.
These data were confirmatory of eight cases published previously [Plant et al. 2011] . A review
of the cases published by Plant et al. shows that four cases were treated within two days after
symptom onset, one case after four days and for the remaining three cases the delay to treatment
initiation was not specified. Taken together half of the case series by Plant et al was treated
within two days after symptom onset, which is comparable to the time interval chosen for
hyperacute treatment initiation in this study. The case series by Plant et al. did not include serial
OCT data [Plant et al. 2011] .
In contrast the ONTT recruited patients within an overall average of five days, permitting for a
delay of up to 14 days [Beck et al. 1992b] . A consistent finding between the ONTT and the
present study was that delay of treatment within this time frame showed a worse outcome. More
specifically the subgroup analysis of present data suggested that the effect of hyperacute
treatment on final visual outcome progressively weakened with delay, failing to reach statistical
significance if initiated later than five days. There is evidence for manifest axonal degeneration
resulting in poor visual outcome within the first two weeks after onset [Petzold,Rejdak & Plant
2004] .
We would however be hesitant to extrapolate from present findings from patient with recurrent
ON to retrospectively interpreting data of a larger population of patients presenting with a first
ever episode of ON. Present data suggest are that in patients with recurrent ON treatment
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initiation within two days is preferable to delayed treatment. Biologically early treatment
initiation is likely to halt inflammation and prevent axonal degeneration [Zhu et al. 1999] .
Nakamura et al had demonstrated that early corticosteroid treatment in patients with NMO-ON
did result in significantly less pRNFL atrophy if compared to patients in whom treatment was
delayed [Nakamura et al. 2010] . This finding by Nakamura et al. is consistent with present OCT
data.
The current study has a number of important limitations. First, the study design was a
retrospective with heterogeneous baseline and follow-up intervals based on clinical practise
needs rather than a clinical trial setting. Statistical analysis corrected for heterogeneity, but
missing data weakened overall statistical power.
Second, in this study only the effect of corticosteroid therapy was evaluated. All patients with
CRION and NMO-ON were on azathioprine and disease modifying treatments were used in MS.
Whist there is no evidence that any of these would have had an effect in acute ON occurring
under this treatment, such co-medication will need to be factored in future trials, not only for
statistics, but also because of ethical concerns regarding placebo controlled trials.
Third, the primary outcome of the current study was the BCVA. This measurement has been used
because it was recorded in the clinical routine, although this might not be the most sensitive
measure. For instance low contrast visual acuity charts are more sensitive and commonly used in
research studies [Balcer,Miller,Reingold & Cohen 2014] . There needs to be rigorous use of
appropriate refraction for sensible collection of low contrast acuity data. Likewise any potential
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future treatment trial on the effect of hyperacute corticosteroids should include visual fields to
complement visual acuity.
These criticism aside, a very recent trial has demonstrated the non-inferiority of oral high-dose
(1000 mg) methyl-prednisolone for three days compared to IVMP (1000 mg) [Le Page et al.
2015] . The importance of this finding cannot be underestimated because it offers for the first
time a realistic option for hyperacute treatment in relapsing optic neuritis.
Conclusion
This study shows that focusing on recurrent optic neuritis may permit to overcome one of the
biggest challenge for optic neuritis treatment trials, namely rapid recruitment. Secondly
hyperacute administration of oral corticosteroids, which are non-inferior to IVMP [Le Page et al.
2015] , may, if given hyperacutely, improve visual outcome. The subgroup analysis suggests that
this may be of particular relevance for patients with RION, CRION and NMO-ON. Clearly, a
prospective study with a rigorous investigation protocol will be needed to investigate this further.
For such a study OCT data on the mGCL should be included as a secondary outcome measure
[Cruz-Herranz et al. 2016]. The demonstration of hyperacute anti-inflammatory activity of
corticosteroids may be further strengthened by inclusion of biomarker data
[Moreira,Tilbery,Monteiro,Teixeira & Teixeira 2006]. Likewise inclusion of biomarkers for
axonal degeneration, neurofilament proteins, at presentation will permit to exclude non-
responders because axonal injury as already incurred [Petzold et al. 2004].
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Methods and materials
Patients
A retrospective explorative case review of consecutive patients presenting to a tertiary specialist
centre (VUmc, NL) with a diagnosis of ON and optical coherence tomography (OCT) data
between January 2010 and January 2014. The study was in accordance with the World Medical
Association (WMA) Declaration of Helsinki and national ethics (http://www.ccmo.nl/nl/uw-
onderzoek-wmo-plichtig-of-niet). The hospital database was searched for the diagnostic codes
for “Optic Neuritis” and “Optic Neuropathy”.
Inclusion criteria
The patients had to be known to the centre and have a diagnosis of multiple sclerosis associated
ON (MSON), relapsing isolated ON (RION), CRION or NMO-ON made following acute optic
neuritis based on established diagnostic criteria [Wingerchuk,Lennon,Pittock,Lucchinetti &
Weinshenker 2006; Polman et al. 2011; Petzold & Plant 2014; Petzold et al. 2014].
The key difference for distinguishing patients with RION from CRION is that patients with
RION experience a spontaneous relapse, whilst patients with CRION will always relapse when
taken off immunosuppressive treatment.
Recurrent episodes of ON were defined as at least two episodes of ON affecting either eye
[Petzold et al. 2014] . Visual acuity (VA) had to be good enough, ≥0.05 decimals, to permit for 
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assessment of longitudinal changes. A baseline OCT scan had to be present. Patients had to be
seen in clinic with each attack. Documented loss of vision on presentation lasting for more than
24 hours was required to qualify for treatment, but pain worsening on eye movements was not a
mandatory criterion as not present in all cases [Petzold et al. 2014] . For a diagnosis of NMO
patients had to be seropositive of AQP4 using a state of the art cell based assay [Wingerchuk et
al. 2015] .
Exclusion criteria
Patients with other causes of visual loss than ON, more than -5 dioptre myopia or transient loss
of vision due to Uhthoff phenomenon [Fraser,Davagnanam,Radon & Plant 2012; Petzold et al.
2014] .
Clinical Assessments
Patient baseline clinical and demographic characteristics were recorded at baseline. The number
of recurrent episodes of ON was noted. We recorded the best corrected visual acuity (BCVA)
using high contrast Snellen charts at presentation and at least three months after a recurrent
episode of ON. The change of BCVA was calculated following each recurrent ON. The BCVA
was used as the primary outcome measure with worse vision indicating poorer outcome.
Treatment
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The treatment was targeted at the aetiology of recurrent ON. Patients with MSON received
methylprednisolone 1000 mg daily for three days. Patients with RION, CRION or NMO-ON had
corticosteroid treatment based on their own preference either intravenously with
methylprednisolone (1000 mg daily for three days) or orally with prednisolone based
individually on what had been the last effective dose during oral taper as borne out during
follow-up [Petzold & Plant 2014] . All patients with CRION and NMO-ON also were on
azathioprine as a steroid saving agent [Petzold & Plant 2014] . Episodes which were not treated
with corticosteroids were defined as “no treatment”.
Retinal OCT
The Spectralis OCT (Heidelberg Engineering) was used as a state of the art spectral domain OCT
device for all patients included. The peripapillary ring scans and macular volume scans were
performed as described [Balk et al. 2014] . To be eligible for data analyses OCT scans had to be
available from baseline and prior to each new episode of recurrent ON and at least three months
after onset. All OCT B-scans were quality controlled and reported as recommended [Tewarie et
al. 2012; Cruz-Herranz et al. 2016] . All scans were automatically segmented using the
Heidelberg Viewing module (version 6.3). Each automatically segmented B-scan was visually
checked for integrity and presence of algorithm failures by one author (EO). The averaged
peripapillary RNFL (pRNFL), averaged macular ganglion cell layer (mGCL, inner 1-2.2 mm
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circle of EDTRS gird) thickness were calculated. The change of pRNFL and mGCL thickness
data between episodes were used as secondary outcome variables, with more atrophy indicating
poorer outcome.
Statistical Analysis
Descriptive statistics were calculated using SAS software (v9.4). Descriptive statistics were
presented for normally distributed data as mean and standard deviation (SD). Normality was
assessed graphically and using the Shapiro–Wilk test. For non-Gaussian data the median and
interquartile range (IQR) were presented. Patients were grouped according to treatment. To
enable statistical analysis the Snellen results were converted to decimal values, using a validated
conversion table which takes into account vision worse than 6/60 [Petzold et al. 2014] . Data
were analysed separately for the affected and unaffected eye per patient and recurrent episode of
ON. The time lag from onset to clinical assessment was added as co-variate. Likewise we
corrected for age, but not for gender as there were only four male subjects. Consecutively
‘hyperacute’ groups were composed of episodes started with treatment within two days because
sustained loss of vision for at least 24 hours was an inclusion criterion. These ‘hyperacute’ group
was compared with groups who consisted of episodes which received delayed treatment and
episodes which received no treatment. Generalised linear models (GLM) were used for
comparison. Two tailed-tests were used and p-value of <0.05 was accepted as statistically
significant.
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Figure legends
Figure 1. Overview of the patient selection process. In total 40 episodes of recurrent ON
occurring in 19 patients had appropriately timed OCT investigations to qualify for inclusion.
Figure 2. Overview episodes per patient and treatment. The number for each patient is shown to
the very left of the graph. Patients were grouped clinically into those with MSON (dark shaded
grey area), CRION (lighter grey shaded area), NMO (lightest grey shaded area) and RION (white
background). For each patient the time from the last episode of recurrent ON to referral to our
centre is shown (number in front of vertical black reference line). At baseline all patients were
seen at our centre and entered to the database (vertical black reference line). Recurrent episodes
of ON were indicated at presentation (circle symbol). The treatment received per presentation
was and colour coded (red filled circle = no treatment, empty circle = delayed treatment, black
filled circle = treatment within 2 days of symptom onset). The cross shows time of last follow-
up.
Figure 3. Change of BCVA following an acute episode of recurrent ON. Patients who received
corticosteroids hyperacutely, within two days, had a significantly better recovery of BCVA
compared to those with delayed treatment initiation (p=0.036) or no treatment at all (p=0.045).
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Figure 4. Change of retinal layer thickness (mGCL = red bars, pRNFL = blue bars) following an
episode of recurrent ON. The y-axis shows the change of individual retinal layer thickness
following an episode of ON. A larger negative value indicates more atrophy. Patients with
hyperacute corticosteroid treatment, within two days, had significantly less atrophy of the
macular mGCL compared to those with delayed treatment initiation (p=0.019). Zero Rx = No
treatment, Slow Rx = Delayed treatment, Quick < 2 Rx = Hyperacute treatment.
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Tables
Table 1. Baseline characteristics of patients with recurrent episodes of ON (pooled). n = number,
IQR = Inter Quartile Range, M = Male, F = Female, RION = relapsing isolated optic neuritis,
CRION = Chronic Relapsing Inflammatory Optic Neuropathy, MSON = Multiple Sclerosis
associated Optic Neuritis, NMO-ON = Neuromyelitis Optica associated ON.
Patients, n 19
Median age (IQR), years 31.0 (26-44)
M:F ratio 4:15
Ethnicity, % Caucasian
Asian
Afro-Caribbean
90%
5%
5%
Median time follow-up (IQR), Months 22 (13-33)
AQP4, n Positive
Negative
2
17
Episodes, n
Total 40
Type, n RION
CRION
MSON
NMO-ON
9
4
4
2
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Table 2. Patient characteristics for the clinical subgroups of patients with recurrent ON. There
were no statistical differences between these groups for the demographic data. But patients with
CRION, RION and NMO-ON had a higher number of recurrent ON compared to those with
MSON. Note that in this table the VA is presented separately for the right and left eye, but the
figures refer to change of visual acuity in the affected eye.
CRION RION MSON NMO-ON
Number of patients, n 4 9 4 2
Median Age (IQR), yr 30.0 (22.5-43.5) 40.0 (30.0-49.0) 25.5 (25.0-34.5) 26.5 (26.0-27.0)
M:F ratio 1:3 1:2 0:4 0:2
Median VA baseline (IQR),
decimal
OD
OS
0.16 (0.002-0.32)
0.2 (0.2-0.2)
0.45 (0.21-0.90)
0.8 (0.4-1.0)
1.0 (0.8-1.0)
0.8 (0.8-1.2)
0.68 (0.10-1.25)
1.0(1.0-1.0)
Median number of recurrent
ON (IQR)
7.75 (3.5-12.0) 5.0 (3.0-8.0) 2.0 (2.0-5.0) 5.0(3.0-7.0)
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Table 3. Corticosteroid treatment per clinical group. This includes episodes prior to referral to
our centre, explaining the lack of treatment of some recurrent episodes in RION and NMO.
Type No treatment Delayed treatment Hyperacute treatment
MSON 86.0% 0.0% 14.0%
RION 25.0% 37.5% 37.5%
CRION 0.0% 55.0% 45.0%
NMO-ON 33.0% 50.0% 17.0%
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Highlights
 Optic neuritis treatment trials have gained new relevance for testing neuroprotective and
remyelination treatment strategies in demyelinating disease.
 Rapid recruitment of patients with a first episode of optic neuritis remains a big challenge
for optic neuritis treatment trials
 Recurrent optic neuritis may offer a chance for rapid recruitment as patients are already
known to the service
 Time is vision
 This retrospective study suggests that rapid patient recruitment to trials is possible with
recurrent optic neuritis
Supplementary Figure : The BCVA of the symptomatic eye (large gray shaded bars) and 
fellow eye (small dotted bars) per treatment group at subsequent time points; (A). within 
three, (B) four, (C) five, (D) six days and (E) comparable to the ONTT after 14 days after 
symptom onset. 
The mean and standard deviation are shown. P- value for treatment groups of affected eyes.
Zero Rx = No treatment. Slow Rx = Delayed treatment, Quick Rx = Hyperacute treatment. 




